

Welcome to the Workshop!



IPAC-RS Workshop: Inhaled Biologics: Preparing for a Future Beyond Small Molecules

September 4-5, 2024





Welcome, Workshop Objectives & Introductions

Presented by Chris Vernall, Intertek, Co-Chair

Background to Workshop

- There are over 200 large molecules in development for either inhaled or nasal delivery, spanning many different modalities.
- Additionally, a huge number of biologics are currently being administered by injection or IV. Inhaled or nasal delivery may represent an attractive alternative, given the potential for targeted delivery to the respiratory system, avoidance of first pass metabolism, rapid onset of action and a better (and less expensive) patient experience.
- In May 2023, an IPAC-RS survey of its Members and Associate Members revealed a strong desire to add an initiative that focused on inhaled and nasal biologics.
- To help define what this new initiative and what its core areas of focus will be, the IPAC-RS Board of Directors
 recommended an organization of a workshop, open to the general public and the IPAC-RS membership, with expert
 speakers covering a wide range of topics.
- Following the expert presentations and discussions, the Workshop Organizing Committee will meet after the Workshop to consider options and recommendations to the IPAC-RS Board for the new biologics focused workstream.

Workshop Objectives

- This IPAC-RS Workshop serves as a meeting place for industry and regulatory thought leaders to consider the
 burgeoning field of pulmonary and nasal delivery of biologics. In developing these types of products, the general
 principles of pharmaceutical aerosol generation for safe and effective delivery to the respiratory tract need to be
 combined with the approaches and techniques suitable for large, complex, and generally fragile entities that fall under
 the umbrella of biologics.
- <u>Day 1</u> will focus on The Inhaled Biologics Landscape, their Critical Quality Attributes, and Aggregation Considerations.
- <u>Day 2</u> will focus on Chemistry, Manufacturing, and Controls for Inhaled Biologic Drug-Device Combinations.
- Through podium presentations from expert speakers and roundtable discussions, attendees will identify current gaps in regulatory science of inhaled and nasal biologics and consider ways to address those gaps through targeted initiatives to be pursued after the Workshop.
- In-person breakout sessions will focus on three major areas: (A) Definitions, Delivery and Manufacturing of Biologic Products; (B) Analytical Testing & Control Strategies; (C) Safety & Toxicological Testing.

Day 1 Agenda

5:00 PM ET

5:00 – 6:30 PM ET

9:00 – 2:30 PM ET **Presentations** Classes of Inhaled and Nasal Biologics: Current Trends in the Industry Tomaso Guidi, Chiesi **Overview of Regulatory Landscape** Ruth Cordoba-Rodriguez, AstraZeneca Testing Requirements for Protein Biologics Therapies Wai Lam Ling, Catalent Preclinical Toxicology: Navigating the Respiratory Tract Barrier Emily Resseguie, Labcorp Early Development Laboratories Testing for Inhaled and Nasal Oligonucleotide and mRNA Products Ashleigh Wake, Intertek Relevance of Protein Aggregates in the Lung Markus Fridén, AstraZeneca 2:30 PM ET Wrap Up and End of Day 1 for Virtual Attendees 3:00 – 5:00 PM ET **Breakouts and Readouts**

End of Day 1 for In-Person Attendees

Networking Reception for In-Person Attendees

Day 2 Agenda

```
9:00 – 2:30 PM ET
                      Presentations
     Excipients for Respiratory Delivery of Large Molecules
           Diana Fernandes, invoX
           Michael Shultz and Kim Shepard, Lonza
      Spray Drying of Biologics
           Sune Klint Andersen, Janssen
      A Platform Approach to Spray Dried, Thermostable, Mucosal Vaccines
           Reinhard Vehring, Access to Advanced Health Institute
     Influence of Device on Aqueous Stability
           Ronan MacLoughlin, Aerogen
     Particle Precision: The Importance of Sample Preparation in Insoluble Particle Analysis in Inhaled Biologic Powders
           Scott Sides, AstraZeneca
     Collection and Detection (Compendial) Strategies for Inhaled Biologics
           Philip J. Kuehl, Lovelace Biomedical
           Christopher J. Gruenloh, PPD, a part of Thermo Fisher Scientific
                      Panel Discussion
2:30 – 3:30 PM ET
3:30 – 3:45 PM ET
                      Closing Remarks
                      End of Workshop
3:45 PM ET
```

Key Points

This Workshop is **your** opportunity to:

- share experiences,
- raise questions,
- learn from each other,
- shape future collaborative initiatives

Therefore, **GET INVOLVED** in the discussions!